Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Thrombocytopenia 1Neutropenia 1Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Breast Neoplasms 1Anemia 1

Interventions

AP 1903 reagent 2thymoglobulin 1obinutuzumab 1fosphenytoin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Thiotepa 1Phenytoin 1Moxibustion 1Melphalan 1Ferric Oxide, Saccharated 1Darbepoetin alfa 1Cyclophosphamide 1CP protocol 1Busulfan 1Antilymphocyte Serum 1Alemtuzumab 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anemia × Moxibustion × Clear all
NCT02781155 2016-05-24

Limiting Chemotherapy Side Effects by Using Moxa

East and North Hertfordshire NHS Trust

Phase 1/2 Unknown
25 enrolled
BreastClassical hematologyGastrointestinal

Anemia, Breast Neoplasms, Genital Neoplasms, Female, Neoplasms, Neutropenia, Thrombocytopenia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡